Correction to: Structure-based design of ASK1 inhibitors as potential agents for heart failure (ACS Medicinal Chemistry Letters (2017) 8:3 (316-320) DOI: 10.1021/acsmedchemlett.6b00481);Structure-Based Design of ASK1 Inhibitors as Potential Agents for Heart Failure

ACS Medicinal Chemistry Letters

Volumn 8, Issue 3, 2017, Pages 316-320

  Lanier, Marion ^a   Pickens, Jason ^a   Bigi, Simone V ^a   Bradshaw Pierce, Erica L ^a   Chambers, Alison ^a   Cheruvallath, Zacharia S ^a   Cole, Derek ^a   Dougan, Douglas R ^a   Ermolieff, Jacques ^a   Gibson, Tony ^a   Halkowycz, Petro ^a   Hirokawa, Aki ^a   Ivetac, Anthony ^a   Miura, Joanne ^a   Nunez, Evan ^a   Sabat, Mark ^a   Tyhonas, John ^a   Wang, Haixia ^a   Wang, Xiaolun ^a   Swann, Steve ^a  

^a TAKEDA PHARMACEUTICALS   (United States)

Author keywords

Apoptosis signal regulating kinase 1 (ASK1); cardiac injury; structure based drug design (SBDD)

Indexed keywords

APOPTOSIS SIGNAL REGULATING KINASE 1 INHIBITOR; CARDIOVASCULAR AGENT; PHOSPHOTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG DESIGN; DRUG STRUCTURE; HEART FAILURE; HEART INFARCTION SIZE; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; PRIORITY JOURNAL;

EID: 85014883869     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.7b00457     Document Type: Erratum

References (12)

1. Izumiya, Y.; Kim, S.; Izumi, Y.; Yoshida, K.; Yoshiyama, M.; Matsuzawa, A.; Ichijo, H.; Iwao, H. Apoptosis Signal-Regulating Kinase 1 Plays a Pivotal Role in Angiotensin II-Induced Cardiac Hypertrophy and Remodeling Circ. Res. 2003, 93, 874-883 10.1161/01.RES.0000100665.67510.F5
2. Saxena, G.; Chen, J.; Shalev, A. Intracellular Shuttling and Mitochondrial Function of Thioredoxin-interacting Protein J. Biol. Chem. 2010, 285, 3997-4005 10.1074/jbc.M109.034421
3. Shiizaki, S.; Naguro, I.; Ichijo, H. Activation mechanisms of ASK1 in response to various stresses and its significance in intracellular signaling Adv. Biol. Regul. 2013, 53, 135-144 10.1016/j.jbior.2012.09.006
4. Tibbles, L. A.; Woodgett, J. R. The stress-activated protein kinase pathways Cell. Mol. Life Sci. 1999, 55, 1230-1254 10.1007/s000180050369
5. Hattori, K.; Naguro, I.; Runchel, C.; Ichijo, H. The roles of ASK family proteins in stress responses and diseases Cell Commun. Signaling 2009, 7, 9-19 10.1186/1478-811X-7-9
6. Terao, Y.; Suzuki, H.; Yoshikawa, M.; Yashiro, H.; Takekawa, S.; Fujitani, Y.; Okada, K.; Inoue, Y.; Yamamoto, Y.; Nakagawa, H.; Yao, S.; Kawamoto, T.; Uchikawa, O. Design and biological evaluation of imidazo[1,2-a] pyridines as novel and potent ASK1 inhibitors Bioorg. Med. Chem. Lett. 2012, 22, 7326-7329 10.1016/j.bmcl.2012.10.084
7. Lin, J. H.; Zhang, J. J.; Lin, S. L.; Chertow, G. M. Design of a phase 2 clinical trial of an ASK1 inhibitor, GS-4997, in patients with diabetic kidney disease Nephron. 2015, 129, 29-33 10.1159/000369152
8. Starosyla, S. A.; Volynets, G. P.; Bdzhola, V. G.; Golub, A. G.; Protopopov, M. V.; Yarmoluk, S. M. ASK1 pharmacophore model derived from diverse classes of inhibitors Bioorg. Med. Chem. Lett. 2014, 24, 4418-4423 10.1016/j.bmcl.2014.08.011
9. Singh, O.; Shillings, A.; Craggs, P.; Wall, I.; Rowland, P.; Skarzynski, T.; Hobbs, C. I.; Hardwick, P.; Tanner, R.; Blunt, M.; Witty, D. R.; Smith, K. J. Crystal structures of ASK1-inhibtor complexes provide a platform for structure-based drug design Protein Sci. 2013, 22, 1071-1077 10.1002/pro.2298
10. 50 - cLogP. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discovery 2007, 6, 881-890 10.1038/nrd2445
11. LE = pIC50 × (−1.4)/HAC where HAC is heavy atom count. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9, 430-431 10.1016/S1359-6446(04)03069-7
12. i)/ΔHAC where HAC is heavy atom count. Verdonk, M. L.; Rees, D. C. Group efficiency: a guideline for hits-to-leads chemistry ChemMedChem 2008, 3, 1179-1180 10.1002/cmdc.200800132